Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus Chemotherapy in Recurrent or Metastatic Endometrial Cancer
NCT06751277Phase 2Not yet recruiting
- Start
- Feb 2025
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of QL1706 in endometrial cancer (EC). Planned start Feb 2025; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT06751277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06751277.